General Information of Drug (ID: DM1I6SO)

Drug Name
2-(3,4,5-Trihydroxy-benzylidene)-malononitrile Drug Info
Synonyms
Tyrphostin A25; Tyrphostin 25; 118409-58-8; Tyrphostin-25; (3,4,5-Trihydroxybenzylidene)-malononitrile; NSC 676484; 2-(3,4,5-Trihydroxybenzylidene)malononitrile; alpha-Cyano-(3,4,5-trihydroxy)cinnamonitrile; AG 82; ((3,4,5-Trihydroxyphenyl)methylene)propanedinitrile; NSC676484; 2-[(3,4,5-trihydroxyphenyl)methylidene]propanedinitrile; NCGC00016046-02; RG-50875; 158129-55-6; Propanedinitrile, ((3,4,5-trihydroxyphenyl)methylene)-; Propanedinitrile,2-[(3,4,5-trihydroxyphenyl)methylene]-; Tyrphostin A 25
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
2061
ChEBI ID
CHEBI:92063
CAS Number
CAS 118409-58-8
TTD Drug ID
DM1I6SO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [2]
VX-680 DM93YKJ Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
JNJ-26483327 DMSQ3AZ Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
ISIS-CRP DMQDUG4 Cardiovascular disease BA00-BE2Z Phase 1 [4]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [5]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [5]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [6]
CI-1040 DMF3DZX Discovery agent N.A. Investigative [5]
AMP-PNP DMTOK1D Discovery agent N.A. Investigative [7]
BMS-536924 DMXJB4N Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
LCK tyrosine protein kinase (LCK) TT860QF LCK_HUMAN Inhibitor [1]

References

1 Tyrphostins. 3. Structure-activity relationship studies of alpha-substituted benzylidenemalononitrile 5-S-aryltyrphostins. J Med Chem. 1993 Nov 12;36(23):3556-64.
2 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
3 National Cancer Institute Drug Dictionary (drug id 596693).
4 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
5 Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
6 Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
7 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
8 Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.